Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
217 studies found for:    Open Studies | "Uterine Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Conditions: Ovarian Cancer;   Uterine Cancer
Interventions: Drug: fosaprepitant including placebo;   Drug: aprepitant including placebo
22 Recruiting Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen
Conditions: Breast Cancer;   Ovarian Cancer;   Cancer of the Uterus
Interventions: Drug: GDC-0032;   Drug: Tamoxifen
23 Unknown  Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence
Conditions: Uterine Cervical Cancer;   Diffusion-weighted MRI;   Recurrence
Intervention: Procedure: Diffusion weighted MRI (DW- MRI)
24 Recruiting Improving the Treatment for Women With Early Stage Cancer of the Uterus
Conditions: Complex Endometrial Hyperplasia With Atypia;   Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions: Drug: Levonorgestrel;   Drug: Metformin
25 Recruiting ADXS11-001 High Dose HPV+ Cervical Cancer
Conditions: Effects of Immunotherapy;   Metastatic/Recurrent Cervical Cancer;   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Cervical Small Cell Carcinoma;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Intervention: Biological: ADXS11-001
26 Recruiting A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
Condition: Adenocarcinoma of the Endometrium
Intervention: Drug: Metformin
27 Recruiting Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Dasatinib;   Drug: Paclitaxel;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis
28 Recruiting Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia
Conditions: Complex Endometrial Hyperplasia With Atypia;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer
Interventions: Behavioral: Weight Loss Specialist;   Other: Quality-of-Life Assessment;   Other: Medical Chart Review
29 Not yet recruiting Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery
Conditions: Fallopian Tube Carcinoma;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Other: Comprehensive Geriatric Assessment;   Other: Questionnaire Administration
30 Recruiting Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function
Condition: Corpus Uteri Carcinoma
Intervention:
31 Recruiting Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Metformin Hydrochloride;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
32 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Glioblastoma;   Adult Soft Tissue Sarcoma;   Adult Solid Neoplasm;   Anaplastic Oligoastrocytoma;   Endometrial Serous Adenocarcinoma;   Estrogen Receptor Negative;   Estrogen Receptor Positive;   Hormone-Resistant Prostate Cancer;   Male Breast Carcinoma;   Metastatic Prostate Carcinoma;   Recurrent Adult Brain Neoplasm;   Recurrent Adult Hepatocellular Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Recurrent Uterine Corpus Sarcoma;   Resectable Hepatocellular Carcinoma;   Stage IA Breast Cancer;   Stage IA Ovarian Cancer;   Stage IA Uterine Corpus Cancer;   Stage IA Uterine Sarcoma;   Stage IB Breast Cancer;   Stage IB Ovarian Cancer;   Stage IB Uterine Corpus Cancer;   Stage IB Uterine Sarcoma;   Stage IC Ovarian Cancer;   Stage IC Uterine Sarcoma;   Stage II Uterine Corpus Cancer;   Stage IIA Breast Cancer;   Stage IIA Lung Carcinoma;   Stage IIA Ovarian Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Breast Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Lung Carcinoma;   Stage IIB Ovarian Cancer;   Stage IIB Skin Melanoma;   Stage IIB Uterine Sarcoma;   Stage IIC Ovarian Cancer;   Stage IIC Skin Melanoma;   Stage IIIA Breast Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Lung Carcinoma;   Stage IIIA Ovarian Cancer;   Stage IIIA Skin Melanoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Breast Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Skin Melanoma;   Stage IIIB Uterine Corpus Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Breast Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Skin Melanoma;   Stage IIIC Uterine Corpus Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Ovarian Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Uterine Corpus Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Corpus Cancer;   Stage IVB Uterine Sarcoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Sirolimus;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
33 Recruiting Incidence of Malignant and Premalignant Endometrial Polyp in Asymptomatic and Symptomatic Postmenopausal Women
Conditions: Endometrial Polyp.;   Malignant and Pre-malignant Changes in the Polyp
Intervention: Procedure: Hysteroscopic polypectomy
34 Recruiting Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Conditions: Endometrial Atypical Hyperplasia;   Endometrial Adenocarcinoma
Interventions: Drug: Megestrol acetate and metformin;   Drug: Megestrol acetate
35 Recruiting Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Conditions: Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
36 Unknown  Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
Condition: Endometrial Cancer
Interventions: Genetic: microarray analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: medical chart review;   Other: study of socioeconomic and demographic variables
37 Not yet recruiting Natural Supplements and a Special Diet in Eliminating Cancer-impacting Hormones From Sources Outside the Body in Patients With Early-Stage or Remission Prostate Cancer, Breast Cancer, or Uterine Cancer
Conditions: Breast Cancer;   Prostate Cancer;   Sarcoma
Interventions: Other: laboratory biomarker analysis;   Procedure: therapeutic dietary intervention
38 Unknown  Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer
Conditions: Malignant Melanoma;   Pancreatic Cancer;   Colon Cancer;   Cervical Cancer
Intervention: Biological: Survivin peptide vaccine
39 Recruiting Cervical Cancer Detection Using Optical Spectroscopy
Condition: Cervical Cancer
Interventions: Device: Optical Spectroscopy Bench-Top System;   Device: Portable Optical Spectrometer;   Device: Transvaginal colposcope
40 Recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: WEE1 Inhibitor MK-1775;   Drug: Gemcitabine Hydrochloride;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years